Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Walgreens has launched the ninth annual Red Nose Day campaign, promoting in-store sales and donations to combat child poverty. From now until May 31, customers can donate via pin-pad or purchase a Red Nose for
InnerScope Hearing Technologies (OTC: INND) has launched its HearingAssist brand of FDA-Registered OTC Rechargeable Hearing Aids on Walgreens.com. This strategic move is part of InnerScope's B2B sales growth strategy, allowing them to reach millions of Walgreens customers. The HearingAssist Rechargeable OTC Hearing Aids, priced between $499 and $799, promise affordability and high-quality features, including Bluetooth connectivity. With over 500,000 hearing aids sold, InnerScope aims to dominate the OTC market by enhancing access to effective hearing solutions.
Walgreens Boots Alliance (WBA) reported its second quarter fiscal 2023 results, revealing a 20.3% decrease in EPS to $0.81, and a 27.2% drop in adjusted EPS to $1.16 due to reduced COVID-19 vaccine and testing volumes. Sales rose 3.3% year-over-year to $34.9 billion. Operating income plummeted to $0.2 billion from $1.2 billion in the previous year, reflecting a $306 million charge related to opioid claims and acquisition costs. Despite challenges, WBA maintains its full-year adjusted EPS guidance at $4.45 to $4.65, expecting growth in core business.
Walgreens confirms its commitment to dispensing Mifepristone where legally allowed, emphasizing adherence to FDA certification and compliance with federal and state laws. The company highlights its role in providing legally approved medications as part of its dedication to community health. Walgreens operates nearly 9,000 retail locations across the U.S., Puerto Rico, and the U.S. Virgin Islands, serving approximately 9 million customers daily. The pharmacy aims to integrate physical and digital platforms to enhance customer experience and meet community health needs.
Walgreens Boots Alliance (WBA) will announce its fiscal 2023 second quarter results on March 28, 2023 at 7 a.m. ET, followed by a conference call with management at 8:30 a.m. ET. The call will be streamed live via WBA's investor relations website. A replay will be available from 11:30 a.m. ET on the same day until April 4, 2023. With over 13,000 locations globally and employing 325,000 people, WBA continues to innovate in healthcare and retail, emphasizing its commitment to community health, sustainability, and digital services.
Walgreens, in collaboration with DoorDash and Uber, has launched a free, Same Day Rx Delivery service for HIV prevention and treatment medications. This service is now available to eligible patients within 15 miles of thousands of Walgreens pharmacies nationwide. This initiative aims to enhance healthcare access, particularly for those in underserved communities, aligning with the White House's National HIV/AIDS strategy targets to reduce new HIV infections significantly by 2030. The move follows previous efforts to provide COVID-19 treatment access, showcasing Walgreens' commitment to tackling health disparities.
Walgreens Boots Alliance (WBA) has sold approximately 15.5 million shares of Option Care Health (OPCH), raising funds at $30.75 per share. This includes 13.0 million shares in an underwritten secondary offering and a concurrent repurchase of 2.5 million shares by OPCH. Following the sale, WBA's ownership in OPCH decreased from 14% to 6%. The proceeds will primarily be allocated for debt paydown and to support WBA's strategic initiatives.
Walgreens is set to host a virtual Supplier Diversity Summit during the week of March 28, aimed at connecting diverse vendors with its merchandising team. This initiative seeks to enhance product offerings from suppliers who are at least 51% owned by disadvantaged groups, including minorities, veterans, and women. The summit will cover categories such as grocery, beauty, health, and wellness. Interested vendors can apply online to participate, fostering local and diverse product solutions for Walgreens' customers across the U.S. This event underscores Walgreens' commitment to meeting the needs of diverse communities.
On January 30, 2023, BetterInvesting Magazine named Lululemon Athletica Inc (NASDAQ: LULU) as its "Stock to Study" and Walgreens Boots Alliance Inc (NASDAQ: WBA) as its "Undervalued Stock" in the April 2023 issue. CEO Ken Zendel emphasized the magazine's role in educating investors, enhancing their market strategies. BetterInvesting offers tools and resources to assist investors in making informed decisions. In the April issue, readers can explore various stocks, while non-members can access trial online stock analysis tools. These selections are meant for informational purposes and do not constitute endorsements for purchase.
Walgreens Boots Alliance (WBA) has declared a quarterly dividend of 48 cents per share, consistent with the last quarter and reflecting a 0.5% increase from the previous year. The dividend will be payable on March 10, 2023, to shareholders of record on February 16, 2023. WBA has a strong history of dividend payments, having paid dividends for 361 consecutive quarters and increased them for 47 consecutive years. This commitment underscores the company's stability and dedication to returning value to investors.